AGA Medical (Golden Valley, California) has joined the growing ranks of companies evaluating the benefit of patent foramen ovale (PFO) closure for the treatment of migraine, saying it has received conditional approval from the FDA to initiate a new study under an existing investigational device exemption to examine the possible connections between migraines and PFOs.